ProfileGDS5678 / 1434565_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 81% 82% 80% 82% 78% 80% 81% 80% 82% 80% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8658982
GSM967853U87-EV human glioblastoma xenograft - Control 25.8717181
GSM967854U87-EV human glioblastoma xenograft - Control 35.7771481
GSM967855U87-EV human glioblastoma xenograft - Control 46.1441982
GSM967856U87-EV human glioblastoma xenograft - Control 55.7439280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8016582
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2899978
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6651880
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7507281
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7597280
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9264182
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.635880
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7732981
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7705281